Skip to main content
. 2020 Nov 10;6(5):1423–1435. doi: 10.1016/j.bioactmat.2020.10.020

Fig. 1.

Fig. 1

Preparation and characterization of SAPEG-MPDA@SPIO/DOX/Fe3+ NPs. (A) Schematic illustration of the preparation of SAPEG-MPDA@SPIO/DOX/Fe3+ NPs. (B) TEM images of SPIO NPs. (C) TEM images of SAPEG-MPDA@SPIO NPs. (D) SEM images of SAPEG-MPDA@SPIO NPs. Particle size distribution (E) and FTIR spectra (F) of MPDA@SPIO, PEG-MPDA@SPIO and SAPEG-MPDA@SPIO NPs. (G) The amount of Fe3+ chelated by PEG-MPDA@SPIO NPs and SAPEG-MPDA@SPIO NPs. (H) The DOX encapsulation efficiency (EE) and drug loading capability (DL) of SAPEG-MPDA@SPIO/Fe3+ NPs. (I) The DOX release profiles of SAPEG-MPDA@SPIO/DOX/Fe3+ NPs. (ns is non-significant, n = 3).